Top Markets
#1 DogBull DogBull +106.14%
#2 Siacoin Siacoin +53.78%
#3 ADO Protocol ADO Protocol +50.84%
#4 The Bitcoin Bull The Bitcoin Bull +43.39%
#5 龙虾 (Lobster) 龙虾 (Lobster) +36.69%
#6 MarsCoin MarsCoin +35.12%
#7 Glidr Glidr +25.30%
#8 UnifAI Network UnifAI Network +19.90%
#9 Ontology Gas Ontology Gas +19.05%
#10 Falcon Finance Falcon Finance +16.87%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd.

2197
Classificação em ações #15712
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on... Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Preço da ação
$0.25841098
Valor de mercado
$335.38M
Variação (1 dia)
-2.42%
Variação (1 ano)
73.70%
País
CN
Negociar Clover Biopharmaceuticals, Ltd. (2197)

Categoria

Healthcare
Margem Operacional de Clover Biopharmaceuticals, Ltd. (2197)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Clover Biopharmaceuticals, Ltd., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Clover Biopharmaceuticals, Ltd. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.